Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure

European Journal of Haematology

Volumn 75, Issue 1, 2005, Pages 27-33

  Knudsen, Lene M ^a,b   Nielsen, Bendt ^a   Gimsing, Peter ^a   Geisler, Christian ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autologous stem cell transplantation; High dose therapy; Multiple myeloma; Renal failure

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; MORPHINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CREATININE CLEARANCE; DIALYSIS; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; CREATININE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 21044439673     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00446.x     Document Type: Article

References (20)

1. KNUDSEN LM, HIPPE E, HJORTH M, HOLMBERG E, WESTIN J for the Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. Eur J Haematol 1994;53:207-212.
2. KNUDSEN LM, HJORTH M, HIPPE E for the Nordic Myeloma Study Group. Renal failure in multiple myeloma with special emphasis on reversibility and the impact on prognosis. Eur J Haematol 2000;64:1-7.
3. ATTAL M, HAROUSSEAU JL, STOPPA AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
4. LENHOFF S, HJORTH M, HOLMBERG E, et al. for the Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
5. CHILD JA, MORGAN GJ, DAVIES FE, OWEN RG, BELL SE, HAWKINS K, BROWN J, DRAYSON MT, SELBY PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue in multiple myeloma. Medical Research Council Adult Leukemia Working Party. N Engl J Med 2003;348:1875-1883.
6. BADROS A, BARLOGIE B, SIEGEL E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-829.
7. SAN MIGUEL JF, LAHUERTA JJ, GARCIA-SANZ R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28-36.
8. 2 as a surrogate marker of outcome in patients with myeloma. B J Cancer 2001;85:325-332.
9. COCKCROFT DW, GAULT H. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. K/DOQI clinical practice guidelines on chronic kidney disease. AJKD 2002;39:1-266.
11. TRICOT G, ALBERTS DS, JOHNSON C, ROE DJ, DORR RT, BRACY D, VESOLE DH, JAGANNATH S, MEYERS R, BARLOGI B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996;2:947-952.
12. ALEXANIAN B, BARLOIGE B, DIXON D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Int Med 1990;150:1693-1695.
13. BLADÉ J, FERNANDEZ-LLAMA P, BOSCH F, MONTOLIU J, LENS XM, MONTOTO S, CASES A, DARNELL A, ROZMAN C, MONTSERRAT E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Int Med 1998;158:1889-1893.
14. SIHORI B, POWLES R, MEHTA J, et al. The implication of compromised renal function at presentation in myeloma. Similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 2001;18:39-50.
15. SCHUH A, DANDRIDGE J, HAYDON P, LITTLEWOOD TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant 1999;24:1141-1143.
16. BALLESTER OF, TUMMALA R, JANSSEN WE, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997;20:653-656.
17. TOSI P, ZAMAGNI E, RONCONI S, BENNI M, MOTTA MR, RIZZI S, TURA S, CAVO M. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000;14:1310-1313.
18. LEE CK, ZANGARI M, BARLOGIE B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823-828.
19. IRISH AB, WINEARLS CG, LITTLEWOOD T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997;90:773-780.
20. PALUMBO A, BERTOLA A, MUSTO P, et al. Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. Blood 2003;102:509a (abstract).